Bioforce Nanosciences Holdings, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
OTC.Pink
BioForce Nanosciences Holdings, Inc. files its 2025 Form 10-K, detailing its transition to nutritional supplements and ongoing financial challenges.
OTC.Pink
BioForce Nanosciences Holdings reports no revenue for FY 2024, a net loss of $490,437, and expresses substantial doubt about its ability to continue as a going concern.
OTC.Pink
BioForce Nanosciences Holdings reported no revenue for the fiscal year 2023 and faces substantial doubt about its ability to continue as a going concern.